Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Bruker (BRKR) due to lower revenues, with a focus on how actual results will compare to estimates impacting stock price [1] Earnings Expectations - Bruker is expected to report quarterly earnings of $0.65 per share, reflecting a year-over-year decrease of 14.5% [3] - Revenue projections stand at $966.4 million, which is a decline of 1.4% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 9.84% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Bruker matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with positive readings being more predictive of earnings beats [9][10] - Bruker currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12] Historical Performance - In the last reported quarter, Bruker exceeded expectations by posting earnings of $0.45 per share against an expected $0.33, resulting in a surprise of +36.36% [13] - Over the past four quarters, Bruker has beaten consensus EPS estimates three times [14] Conclusion - While Bruker may not appear to be a strong candidate for an earnings beat, investors should consider other factors before making investment decisions [17]

Core Viewpoint - The market anticipates Check Point Software (CHKP) to report a year-over-year increase in earnings driven by higher revenues for the quarter ending December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on February 12, with a consensus EPS estimate of $2.77, reflecting a +2.6% year-over-year change, and revenues projected at $746.02 million, up 6% from the previous year [3][2]. - The consensus EPS estimate has been revised 1.74% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that Check Point has a positive Earnings ESP of +0.08%, suggesting analysts have recently become more optimistic about the company's earnings prospects [12]. - The stock currently holds a Zacks Rank of 3, indicating a neutral outlook, but the combination of a positive Earnings ESP suggests a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Check Point exceeded the expected EPS of $2.45 by delivering $3.94, resulting in a surprise of +60.82% [13]. - Over the past four quarters, the company has consistently beaten consensus EPS estimates [14]. Conclusion - Check Point is viewed as a strong candidate for an earnings beat, but investors are advised to consider additional factors beyond earnings results when making investment decisions [17].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for DexCom, with a focus on how actual results compare to estimates impacting stock price [1][2] Earnings Expectations - DexCom is expected to report quarterly earnings of $0.65 per share, reflecting a year-over-year increase of +44.4% [3] - Revenues are projected to reach $1.25 billion, representing a 12.5% increase from the previous year [3] Estimate Revisions - The consensus EPS estimate has been revised 0.21% lower in the last 30 days, indicating a reassessment by analysts [4] - The direction of estimate revisions may not always align with the aggregate change [4] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for DexCom is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +4.75% [12] - DexCom currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, DexCom exceeded the expected earnings of $0.57 per share by delivering $0.61, resulting in a surprise of +7.02% [13] - Over the past four quarters, DexCom has beaten consensus EPS estimates two times [14] Conclusion - While an earnings beat may influence stock movement, other factors can also play a significant role in stock performance [15] - Monitoring Earnings ESP and Zacks Rank is crucial for making informed investment decisions ahead of earnings releases [16]

Core Viewpoint - Materion (MTRN) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for February 12, and it could positively impact the stock if the results exceed expectations; conversely, missing estimates may lead to a decline in stock price [2]. - The Zacks Consensus Estimate predicts quarterly earnings of $1.58 per share, reflecting a year-over-year increase of 1.9%, with revenues expected to reach $461 million, a 5.5% increase from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 17.71%, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Materion is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.27%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, with positive readings being more reliable [9][10]. - Materion's current Zacks Rank is 3, which complicates the prediction of an earnings beat given the negative Earnings ESP [12]. Historical Performance - In the last reported quarter, Materion met the expected earnings of $1.41 per share, resulting in no surprise, and has beaten consensus EPS estimates three times over the last four quarters [13][14]. Conclusion - Materion does not currently appear to be a strong candidate for an earnings beat, and investors should consider additional factors when deciding on their investment strategy ahead of the earnings release [17].

Wall Street expects a year-over-year increase in earnings on higher revenues when PG&E (PCG) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 12, might help the stock move higher if these key numbers are better than expectations. ...

Company Overview - Zoetis (ZTS) is expected to report flat earnings of $1.40 per share for the quarter ended December 2025, with revenues projected at $2.37 billion, reflecting a 2.1% increase from the previous year [3]. Earnings Expectations - The consensus EPS estimate has been revised 0.26% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4]. - A positive Earnings ESP of +0.84% suggests that analysts are optimistic about Zoetis's earnings prospects, although the company holds a Zacks Rank of 3 [12]. Historical Performance - In the last reported quarter, Zoetis exceeded the expected earnings of $1.62 per share by delivering $1.70, resulting in a surprise of +4.94% [13]. - Over the past four quarters, Zoetis has consistently beaten consensus EPS estimates [14]. Industry Context - In comparison, Neurocrine Biosciences (NBIX) is expected to post earnings of $2.25 per share for the same quarter, marking a significant year-over-year increase of +125%, with revenues anticipated to rise by 25% to $784.42 million [18].

分组1 - XPO reported quarterly earnings of $0.88 per share, exceeding the Zacks Consensus Estimate of $0.76 per share, but down from $0.89 per share a year ago, representing an earnings surprise of +16.25% [1] - The company achieved revenues of $2.01 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 3.47% and up from $1.92 billion year-over-year [2] - XPO has outperformed the S&P 500 with a 32.1% increase in shares since the beginning of the year, compared to the S&P 500's gain of 0.5% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.79 on revenues of $2 billion, and for the current fiscal year, it is $4.27 on revenues of $8.36 billion [7] - The Transportation - Truck industry, to which XPO belongs, is currently ranked in the bottom 5% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Another trucking company, Saia, is expected to report quarterly earnings of $1.90 per share, reflecting a year-over-year decline of -33.1%, with revenues projected at $780.61 million, down 1.1% from the previous year [9][10]

Core Viewpoint - Cardinal Health, Inc. has shown significant stock performance, outperforming major indices and demonstrating strong earnings growth potential Company Overview - Founded in 1979, Cardinal Health, Inc. is based in Dublin, Ohio, and operates as a healthcare services and products company both in the United States and internationally [1] - The company has a market capitalization of $49.1 billion and operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution [1] Stock Performance - CAH stock has surged 65.3% over the past 52 weeks, significantly outperforming the S&P 500 Index, which returned 14% during the same period [1] - The stock has also outperformed the State Street Healthcare Select Sector SPDR ETF's (XLV) 6.1% rise over the past 52 weeks [2] Earnings Forecast - On January 13, Cardinal Health raised its full-year adjusted EPS forecast to at least $10.00 from a previous range of $9.65-$9.85, exceeding the consensus estimate of $9.83 [3] - For the fiscal year ending in June 2026, analysts expect CAH to report a 22.1% year-over-year growth in adjusted EPS to $10.06 [3] - The company has a strong earnings surprise history, surpassing bottom-line estimates in each of the past four quarters [3] Analyst Ratings - CAH has a consensus "Strong Buy" rating overall, with 13 out of 16 analysts recommending "Strong Buy" and three recommending "Hold" [4] - Analyst sentiment has become increasingly bullish, with the number of "Strong Buy" recommendations rising from 12 a month ago to 13 [5] Price Targets - CAH's mean price target of $234 indicates a 13.1% premium to current market prices [6] - The Street-high target of $270 suggests a robust 30.5% upside potential from current price levels [6]

Core Viewpoint - Sempra (SRE) has shown mixed performance in the market, with recent earnings surpassing estimates but overall stock performance lagging behind broader indices and sector benchmarks [2][3][6]. Company Overview - Sempra, founded in 1996 and based in San Diego, California, is an energy services holding company involved in the sale, distribution, storage, and transportation of electricity and natural gas, with a market capitalization of $56.8 billion [1]. Stock Performance - Over the past 52 weeks, SRE stock has grown by 6.4% but has declined by 1.9% year-to-date, underperforming the S&P 500 Index, which has returned 14% in the same period [2]. - SRE has also underperformed the State Street Utilities Select Sector SPDR ETF (XLU), which rose by 11% over the past year [3]. Earnings Report - In Q3 2025, Sempra reported revenue of $3.2 billion, a 13.5% year-over-year increase, exceeding Wall Street estimates. The adjusted EPS was $1.11, surpassing estimates by 19.4% [6]. - For the fiscal year ending December 2025, analysts expect a 1.7% year-over-year decline in adjusted EPS to $4.57, with a mixed earnings surprise history [7]. Analyst Ratings - Among 18 analysts covering SRE, the consensus rating is "Moderate Buy," with 11 "Strong Buy" ratings, one "Moderate Buy," and six "Holds," indicating a bullish trend in recent months [8]. - Barclays analyst Nicholas Campanella maintained an "Overweight" rating on Sempra and adjusted the price target from $97 to $95, with a mean price target of $100.57 suggesting a potential upside of 16.1% [9].

Core Insights - CyberArk reported revenue of $372.65 million for the quarter ended December 2025, marking an 18.5% year-over-year increase and a 4.7% surprise over the Zacks Consensus Estimate of $355.91 million [1] - The company achieved an EPS of $1.33, which is a significant increase from $0.80 a year ago, resulting in an EPS surprise of 18.12% compared to the consensus estimate of $1.13 [1] Financial Performance Metrics - Total Annual Recurring Revenue (ARR) reached $1.44 billion, slightly above the average estimate of $1.43 billion from three analysts [4] - Maintenance ARR was reported at $173 million, below the average estimate of $178.25 million from three analysts, reflecting a decline [4] - Subscription ARR totaled $1.27 billion, exceeding the average estimate of $1.25 billion from three analysts [4] - Subscription revenues were $310.52 million, surpassing the estimated $296.84 million by five analysts, representing a 27.8% increase year-over-year [4] - Revenues from maintenance and professional services were $62.13 million, above the estimated $57.76 million by five analysts, but this reflects a 6.4% decrease compared to the year-ago quarter [4] Stock Performance - CyberArk's shares have returned -9.6% over the past month, contrasting with the Zacks S&P 500 composite's +0.9% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]